Advertisement

Role of Sodium Fluoride-PET in Primary Bone Tumors

  • Vivek Subbiah
  • Kalevi Kairemo
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Malignant bone tumors are classified based on the histological origin. The nomenclature is based on the predominant components of the malignancy. Osteogenic sarcoma (osteosarcoma), chondrosarcoma, and Ewing’s sarcoma are primary bone tumors. Although multiple myeloma is the most common primary bone tumor it is considered a marrow cell tumor and not one arising from the bone. The incidence of the primary bone tumors vary depending upon the age (Table 9.1). Owing to the ability to metastasize and progress rapidly they are a cause of major morbidity and mortality. Osteosarcoma and Ewing’s sarcoma strike adolescents and young adults in the prime of their lives. Conventional imaging modalities for staging and restaging include bone scintigraphy with SPECT/CT, CT scan, MRI, and PET/CT scan. More recently sodium fluoride PET/CT scan has become available. The benefit of using sodium fluoride PET/CT in malignant primary bone tumors is characterized by detectable bone formation in soft-tissue. Herein, we discuss the role of sodium fluoride PET/CT scan in imaging of primary bone tumors specifically osteosarcoma and giant cell tumor of the bone. We also present the role of sodium fluoride PET/CT in staging, monitoring, and evaluation of response in malignant primary bone tumors.

Keywords

Na18F PET 18F-FDG PET Bone scintigraphy 

References

  1. 1.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.CrossRefGoogle Scholar
  2. 2.
    Subbiah V, Anderson P, Rohren E. Alpha emitter radium 223 in high-risk osteosarcoma: first clinical evidence of response and blood-brain barrier penetration. JAMA Oncol. 2015;1(2):253–5.CrossRefGoogle Scholar
  3. 3.
    Kairemo K, Wang WL, Subbiah V. Comprehensive molecular imaging of malignant transformation of giant cell tumor of bone reveals diverse disease biology. BMJ Case Rep. 2019;12(4). pii: e218839.  https://doi.org/10.1136/bcr-2016-218839.CrossRefGoogle Scholar
  4. 4.
    Kairemo K, Rohren EM, Anderson P, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. Development of Sodium Fluoride-PET Response Criteria for Solid tumors (NAFCIST) in a clinical trial of Radium 223 in Osteosarcoma: From RECIST to PERCIST to NAFCIST. ESMO Open. 2019;4(1):e000439.CrossRefGoogle Scholar
  5. 5.
    Verma P, Purandare N, Agrawal A, Shah S, Rangarajan V. Unusual finding of a tumor Thrombus arising from osteosarcoma detected on 18F-NaF PET/CT. Clin Nucl Med. 2016;41(6):e304–6.CrossRefGoogle Scholar
  6. 6.
    Usmani S, Marafi F, Rasheed R, Bakiratharajan D, Al Maraghy M, Al Kandari F. Unsuspected metastases to muscles in osteosarcoma detected on 18F-sodium fluoride PET/CT. Clin Nucl Med. 2018;43(9):e343–e5.CrossRefGoogle Scholar
  7. 7.
    Jackson T, Mosci C, von Eyben R, Mittra E, Ganjoo K, Biswal S, et al. Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients. Clin Nucl Med. 2015;40(9):720–4.CrossRefGoogle Scholar
  8. 8.
    Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010;102(4):651–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Vivek Subbiah
    • 1
  • Kalevi Kairemo
    • 2
    • 3
  1. 1.Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Unit 455, Division of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Nuclear Medicine and Molecular RadiotherapyDocrates Cancer CenterHelsinkiFinland
  3. 3.Department of Nuclear MedicineUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations